Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 7/2/15 )$62.33
Total Net Assets (As of 5/31/15)$4.83B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 6/30/15)
1 Year40.08%
3 Year39.10%
5 Year31.38%
10 Year15.39%
Morningstar (As of 5/31/15)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

123 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Quarterly Commentary - Q1 2015

EXECUTIVE SUMMARY

Quarterly returns in health care outpaced those of the broader market and were driven by a surge in merger and acquisition activity, especially among biotechnology names.

Biotechnology companies drove Fund performance,while health care technology stocks detracted most from relative results.

Pharmacyclics led contributors, followed by Valeant Pharmaceuticals and Biogen Idec.

We expect the wave of innovative therapies aimed at the highest, unmet medical needs to continue into the foreseeable future.

FUND MANAGEMENT

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996